Current treatments for type 2 diabetes include metformin [22] and thiazolidinediones, which mediate some of their therapeutic effects by activation of AMPK [23], essentially through lowering hepatic glucose production. The gene discussed is PRKAA2; the disease is type 2 diabetes mellitus.